Tony's Chocolonely recalls chocolate bars that may contain stones
NEW YORK (PIX11) — A New York based chocolate company has pulled two of its products from store shelves.
Tony's Chocolonely recalled seven lots of its Dark Almond Sea Salt Bar and Everything Bar on Tuesday. The company warns that the products may contain small stones following 12 reports of people finding them.
More Local News
The recalled products were sold in multiple retail stores across the United States and online from Feb. 7 to March 24.
Anyone who may have bought the chocolate bars is warned to return them for a refund or throw them away.
More: Latest News from Around the Tri-State
Below is a list of lot codes for the recalled products.
Tony's Chocolonely Everything Bar
4327
4330
4331
M4331
Tony's Chocolonely Dark Chocolate Almond Sea Salt
163094
162634
M162634
Dominique Jack is a digital content producer from Brooklyn with more than five years of experience covering news. She joined PIX11 in 2024. More of her work can be found here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Oscar Health, Inc. (OSCR) Laps the Stock Market: Here's Why
Oscar Health, Inc. (OSCR) closed at $14.34 in the latest trading session, marking a +1.34% move from the prior day. This change outpaced the S&P 500's 0.38% gain on the day. At the same time, the Dow added 0.24%, and the tech-heavy Nasdaq gained 0.24%. Shares of the company witnessed a loss of 14.45% over the previous month, trailing the performance of the Finance sector with its gain of 2.88%, and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of Oscar Health, Inc. in its upcoming release. The company's upcoming EPS is projected at $0.34, signifying a 70.00% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $2.86 billion, reflecting a 28.96% rise from the equivalent quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.61 per share and a revenue of $11.21 billion, representing changes of +510% and +22.12%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Oscar Health, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 11.11% decrease. Oscar Health, Inc. is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that Oscar Health, Inc. has a Forward P/E ratio of 23.07 right now. This expresses a premium compared to the average Forward P/E of 9.92 of its industry. The Insurance - Multi line industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 92, placing it within the top 38% of over 250 industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oscar Health, Inc. (OSCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Duolingo, Inc. (DUOL) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Duolingo, Inc. (DUOL) was up +1.63% at $481.48. This change outpaced the S&P 500's 0.38% gain on the day. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%. Heading into today, shares of the company had lost 12.37% over the past month, lagging the Business Services sector's gain of 3.09% and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of Duolingo, Inc. in its upcoming release. The company is predicted to post an EPS of $0.55, indicating a 7.84% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $241.04 million, indicating a 35.17% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates are projecting earnings of $2.92 per share and revenue of $997.46 million, which would represent changes of +55.32% and +33.35%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Duolingo, Inc. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Duolingo, Inc. is currently sporting a Zacks Rank of #2 (Buy). In terms of valuation, Duolingo, Inc. is presently being traded at a Forward P/E ratio of 162.12. This represents a premium compared to its industry average Forward P/E of 19.78. It is also worth noting that DUOL currently has a PEG ratio of 3.61. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Technology Services industry had an average PEG ratio of 1.43. The Technology Services industry is part of the Business Services sector. This industry, currently bearing a Zacks Industry Rank of 46, finds itself in the top 19% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Duolingo, Inc. (DUOL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
2 hours ago
- Yahoo
The European Commission Approves Alnylam's AMVUTTRA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM). A researcher studying genetic medicines under a microscope in a biopharmaceutical laboratory. As a result, AMVUTTRA is the first and only RNAi treatment approved in the EU for transthyretin amyloidosis symptoms that show as cardiomyopathy and polyneuropathy. The HELIOS-B Phase 3 research, which revealed a 36% mortality reduction over 42 months and a 28% decrease in all-cause mortality and recurrent cardiovascular events, served as the basis for the approval. More than 6,000 patient-years of safety data support the quarterly administration of the medication. The drug is already authorized in Brazil and the United States. Up to 100,000 individuals in Europe have ATTR amyloidosis, mostly as cardiomyopathy. An RNAi treatment called vutrisiran provides continuous knockdown by stopping TTR production at its source with quarterly injections. Functional and quality-of-life gains were validated by the HELIOS-B trial, which involved patients on SGLT2 inhibitors and tafamidis. Elevations of liver enzymes and injection site responses are frequent adverse effects. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is an innovator in the investigation of RNA interference medicines. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
